Literature DB >> 2442947

Methotrexate treatment of psoriatic arthritis.

H Zachariae, E Zachariae.   

Abstract

A prospective study was carried out over 12 months involving twenty-eight patients with psoriatic arthritis. Almost all patients improved dramatically with regard to both pain and function. Clinical assessment including evaluation of number of swollen joints, joint tenderness score, and morning stiffness was performed by external observer without any knowledge of previous evaluation data. These data together with patients' assessment of pain and assessment of general condition, consumption of analgetics, and sedimentation rate improved significantly after three and six or twelve months. Apart from transient increases in serum transaminases no other abnormalities developed during the study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442947

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

Review 1.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Real-life experience of using conventional disease-modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA). Retrospective analysis of the efficacy of methotrexate, sulfasalazine, and leflunomide in PsA in comparison to spondyloarthritides other than PsA and literature review of the use of conventional DMARDs in PsA.

Authors:  Euthalia Roussou; Aicha Bouraoui
Journal:  Eur J Rheumatol       Date:  2017-03-01

Review 3.  Diagnosis and management of psoriatic arthritis.

Authors:  John Brockbank; Dafna Gladman
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.